

Resource Summary Report

Generated by T1D on Aug 6, 2026

COSMIC - Catalogue Of Somatic Mutations In Cancer

RRID:SCR_002260

Type: Tool

Proper Citation

COSMIC - Catalogue Of Somatic Mutations In Cancer (RRID:SCR_002260)

Resource Information

URL: <http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>

Proper Citation: COSMIC - Catalogue Of Somatic Mutations In Cancer (RRID:SCR_002260)

Description: Database to store and display somatic mutation information and related details and contains information relating to human cancers. The mutation data and associated information is extracted from the primary literature. In order to provide a consistent view of the data a histology and tissue ontology has been created and all mutations are mapped to a single version of each gene. The data can be queried by tissue, histology or gene and displayed as a graph, as a table or exported in various formats.

Some key features of COSMIC are:

- * Contains information on publications, samples and mutations. Includes samples which have been found to be negative for mutations during screening therefore enabling frequency data to be calculated for mutations in different genes in different cancer types.
- * Samples entered include benign neoplasms and other benign proliferations, in situ and invasive tumours, recurrences, metastases and cancer cell lines.

Abbreviations: COSMIC

Synonyms: Catalogue Of Somatic Mutations In Cancer

Resource Type: data or information resource, database

Defining Citation: [PMID:20952405](#)

Keywords: cancer, mutation, somatic mutation, tumor, cancer genome, genome, gene, dna, tissue, histology, bio.tools, FASEB list

Related Condition: Cancer

Funding: Wellcome Trust 077012/Z/05/Z

Availability: Free

Resource Name: COSMIC - Catalogue Of Somatic Mutations In Cancer

Resource ID: SCR_002260

Alternate IDs: nif-0000-02690, biotools:cosmic, OMICS_00082

Alternate URLs: <http://www.sanger.ac.uk/perl/CGP/cosmic>, <https://bio.tools/cosmic>

Record Creation Time: 20220129T080212+0000

Record Last Update: 20260806T054336+0000

Ratings and Alerts

No rating or validation information has been found for COSMIC - Catalogue Of Somatic Mutations In Cancer.

No alerts have been found for COSMIC - Catalogue Of Somatic Mutations In Cancer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4486 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Vlachos G, et al. (2026) Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility. British journal of cancer.

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. JGH open : an open access journal of gastroenterology and hepatology, 10(1), e70331.

Chow Z, et al. (2026) Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison. HGG advances, 7(1), 100527.

Botticelli A, et al. (2026) The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 45.

Xiong Z, et al. (2026) C/EBP β -induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma. Cellular & molecular immunology, 23(1), 94.

Hsu HC, et al. (2026) Expression of Bacillus in colorectal tissues is associated with improved cetuximab therapy for patients with metastatic colorectal cancer. Translational

oncology, 63, 102575.

Struys I, et al. (2025) Prenatal Exposure to Chemotherapy Increases the Mutation Burden in Human Neonatal Hematopoietic Stem Cells. *Cancer discovery*, 15(5), 903.

Concin N, et al. (2025) GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3160.

Garcia GL, et al. (2025) Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. *Cancer discovery*, 15(6), 1203.

Sato S, et al. (2025) Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. *Neoplasia (New York, N.Y.)*, 64, 101158.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. *Blood cancer discovery*, 6(6), 580.

LaFlam TN, et al. (2025) Phenotypic pleiotropy of missense variants in human B cell confinement receptor P2RY8. *Cell genomics*, 100981.

Bayati M, et al. (2025) Cancer Genomic Alterations and Microenvironmental Features Encode Synergistic Interactions with Disease Outcomes. *Molecular cancer research : MCR*, 23(12), 971.

Yadav S, et al. (2025) Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(21), 4463.

Chaudhary R, et al. (2025) Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3678.

Sawant A, et al. (2025) Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes. *Cancer research*, 85(6), 1130.

Laplane P, et al. (2025) Effect of Mismatch repair deficiency on metastasis occurrence in a syngeneic mouse model. *Neoplasia (New York, N.Y.)*, 62, 101145.

Toyokuni E, et al. (2025) Combination therapy of avutemetinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer. *Molecular cancer therapeutics*.

Ghani H, et al. (2025) GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling. *Cancer research communications*, 5(9), 1477.